BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Emil Kakkis harvesting academic sources for Orphan drug newco Ultragenyx
News | 12. 19. 2011
Ultragenyx Pharmaceutical
Emil Kakkis harvesting academic sources for Orphan drug newco Ultragenyx
By Jennifer Rhodes
Staff Writer
Published on Monday, December 19, 2011
Ultragenyx Pharmaceutical Inc. is taking a traditional approach to Orphan Drugs by in-licensing development-ready substrate and enzyme replacement therapies that have a clear mechanistic rationale and proof of concept in animals for rare and ultra-rare genetic diseases.
Founder, President and CEO Emil Kakkis believes there are a few hundred such diseases with no current treatments.
